Save time and jump to the most important pieces.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
10/1/2021 | $8.00 | Buy | Ascendiant Capital Markets |
Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Data will guide upcoming "Lithium in Brain" Phase II clinical trials in partnership with Massachusetts General Hospital, which were announced in August 2024 Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announc
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq") that Alzamend has demonstrated compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), which requires a minimum stockholders' equity of $2,500,000. As previously reported, on September 26, 2023, Alzamen
Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that CEO Stephan Jackman will participate in a fireside chat at the upcoming Maxim Group Virtual Healthcare Conference. The conversation will take place with a senior member of Maxim Group's biotech research team on Thursday, October 17, 2024, at 1:30 pm ET. Mr. Jackman looks forward to providing an overview of Alzamen
15-12G - Ault Disruptive Technologies Corp (0001864032) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
25-NSE - Ault Disruptive Technologies Corp (0001864032) (Subject)
Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00
4 - Ault Disruptive Technologies Corp (0001864032) (Issuer)
4 - Algorhythm Holdings, Inc. (0000923601) (Issuer)
4 - Algorhythm Holdings, Inc. (0000923601) (Issuer)
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), announced the results of the Company's 2022 Annual Meeting of Stockholders (the "Meeting"), which was held today, November 23, 2022, at 9:00 a.m. PT, and at which time the nominees for election as directors set forth in Proposal 1 were each re-elected and Proposals 2, 3, 6 and 7 were each approved by the stockholders. Proposals 4 and 5 were not approved by the stockholders. At the Meeting, the stockholders voted upon and approved the following proposals as described in the Proxy Statement: Election of the seven director nominees named in the Proxy Statement to hold office until the next annual
Company Appoints Veteran Developer Douglas Gintz as President and Chief Product Officer to Lead the Effort BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), announced today that its subsidiary, BitNile, Inc. ("BNI"), has begun development of a Bitcoin-based marketplace platform ("Marketplace"), which expects to leverage blockchain and other emerging technologies. BNI believes that the Marketplace will reduce the complexity of transacting in Bitcoin and result in lower transaction fees than traditional e-commerce. The Marketplace, planned for release in the first half of 2023, will be a multi-vendor e-commerce platform supporting a wide array of
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
SC 13G/A - Ault Disruptive Technologies Corp (0001864032) (Subject)
SC 13G/A - Ault Disruptive Technologies Corp (0001864032) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker RIME. Fort Lauderdale, FL, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. ("Singing Machine") (NASDAQ: MICS) – the worldwide leader in consumer karaoke products, recently announced it has successfully completed the acquisition of SemiCab, Inc. ("SemiCab"), a leading artificial intelligence technology company in the global logistics space. As part of this transaction, the Company announced an expanded business model, centered on making investments in AI driven technology companies focused on solving challenges for some of the largest global industry verticals. Today, the Comp
Fort Lauderdale, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. ("Singing Machine" or the "Company") (NASDAQ: MICS) -- the worldwide leader in consumer karaoke products -- today announced that its earnings for its second quarter of 2024 will be released Monday, August 19, 2024. The same day Management will host a conference call at 4:00 PM Eastern time to discuss the financial results and provide a business update. Management will also provide an update on the acquisition integration of SemiCab, an emerging AI-powered technology provider serving the global logistics space. Conference Call Details: Date: Monday August 19, 2024Time: 4:00 PM EDT Dial-in number: 800-
SemiCab India Expected to Add Over $9 Million in Revenue in 2024 Fort Lauderdale, FL, July 16, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. ("Singing Machine") (NASDAQ: MICS) – the worldwide leader in consumer karaoke products, recently announced it has successfully completed the acquisition of SemiCab, Inc. ("SemiCab"), a leading artificial intelligence technology company in the global logistics space. Today, the Company provided an update on the integration process for the newly created operations under SemiCab Holdings, LLC. The Company currently has key executives in India, completing the final prerequisites for the acquisition of SMCB Solutions Private Limited ("SMCB"